{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040701","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.502250+00:00","generated_at":"2026-06-08T03:55:56.646910+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lucid Q3 EsoGuard rev $783K (+392% seq.), net loss $14.2M","bullets":["EsoGuard test volume 2,575 (17% sequential increase, 137% YoY).","EsoGuard revenue $783K, up 392% sequentially and 930% YoY; net loss $14.2M ($0.34 per share).","Non-GAAP adjusted loss $9.3M ($0.22 per share); cash $24.1M vs $32.6M at June 30.","Clinical utility data: near-perfect concordance from three studies totaling over 1,500 patients.","EsoGuard 2.0 launched with multiplexed triplicate consensus; NGS platform upgrade underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040701","json":"https://secwatch.observer/filing/0001493152-23-040701.json","markdown":"https://secwatch.observer/filing/0001493152-23-040701.md","text":"https://secwatch.observer/filing/0001493152-23-040701.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/0001493152-23-040701-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:55:56.646910+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be8f85e1a3a493729f547196b772a78f0be3a46b","claim":"Lucid Diagnostics Inc. reported the three and nine months ended September 30, 2023 results: revenue $0.8 million, net income $14.2 million, or $(0.34) per common share, EPS $(0.34) per common share.","evidence_excerpt":"and platform expected to significantly lower per-sample sequencing costs. Financial Results ● For the three months ended September 30, 2023, EsoGuard related revenues were $0.8 million. Operating expenses were approximately $11.9 million, including stock-based compensation expenses of $1.3 million. GAAP net loss was approximately $14.2 million, or $(0.34) per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/0001493152-23-040701-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$0.8 million"},{"label":"Net income","value":"$14.2 million, or $(0.34) per common share"},{"label":"EPS","value":"$(0.34) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}